Galmed Pharmaceuticals Ltd.
GLMD · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $7,265 | $2,563 | $5,126 | $474 |
| - Cash | $4,964 | $4,767 | $4,652 | $9,724 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2,301 | -$2,204 | $474 | -$9,250 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2,109 | -$1,264 | -$1,644 | -$2,011 |
| % Margin | – | – | – | – |
| Net Income | -$2,495 | -$1,104 | -$3,209 | -$1,914 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.63 | -0.62 | -46.42 | -27.69 |
| % Growth | -1.6% | 98.7% | -67.6% | – |
| Operating Cash Flow | -$1,268 | -$1,167 | -$1,969 | -$1,064 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,268 | -$1,167 | -$1,969 | -$1,064 |